Sponsor:
Shanghai Henlius Biotech
Code:
NCT05468489
Conditions
Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapy (carboplatin-etoposide)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by Shanghai Henlius Biotech on 2025-03-25.